Tag: Ceftobiprole

First approved by the FDA in 2010, the first 5th generation antibiotic, ceftaroline, was a major breakthrough in combating multi-drug resistant bacteria, especially Methicillin-Resistant *Staphylococcus aureus* (MRSA). These advanced cephalosporins represent a crucial front-line defense against some of the most formidable bacterial infections in modern medicine.

In April 2024, the US Food and Drug Administration (FDA) approved the novel cephalosporin antibiotic Zevtera (ceftobiprole medocaril), providing a new answer to the urgent question, "What is the new drug for MRSA?". This milestone introduces a crucial new weapon against a persistent and deadly superbug, offering physicians an additional tool for serious and complex infections.